Table 2.
Cellular therapies
| Cellular therapy | N | Patient population | ORR | CR | Grade 3 CRS/NT | Grade 3 AE | Ref |
|---|---|---|---|---|---|---|---|
| ET190L1-ArtemisTM Therapy | 21 | DLBCL, FL,MCL, SLL/CLL, splenic MZL | 52% | 24% | None | Lymphopenia, neutropenia, tremor, fever, rash | [19] |
| Bispecific CAR (CD-19/CD-20) | 7 | DLBCL, ALL | 60% (DLBCL) | 40% (DLBCL) | None | None | [23] |
| Bispecific CAR (CD-19/CD-20) | 6 | DLBCL, FL, MCL,CLL | 50% | 33% | None | None | [24] |
| Bispecific CAR (CD-19/CD-22) | 6 | DLBCL, tFL, tMZL | 80% | 40% | 1 patient (20%)—NT | Neutropenia, thrombocytopenia, hypophosphatemia, neurotoxicity | [25] |
| Armored CAR T cells | 25 | DLBCL ,CLL, tFL, FL, WM | 72% | 57% | 2 patients (8%)—NT | Neurotoxicity | [26] |
| ACTR 087 | 7 | r/r NHL | 50% | 33% | None | Neutropenia, leukopenia | [27] |
| ACTR 707 | 6 | DLBCL, FL | NA | 50% | None | Febrile neutropenia | [28] |
Abbreviations: N number of patients, ORR overall response rate, CR complete response rate, CRS cytokine release syndrome, NT neurotoxicity, AE adverse events, DLBCL diffuse large B cell lymphoma, CLL chronic leukemic leukemia, tFL transformed follicular lymphoma, FL follicular lymphoma, WM Waldenström’s macroglobulinemia, MCL mantle cell lymphoma, tMZL transformed marginal zone lymphoma, ALL acute lymphoblastic leukemia, NHL non-Hodgkin lymphoma, MZL marginal zone lymphoma, NA data unavailable